Office Action Predictor
Last updated: April 16, 2026
Application No. 19/193,629

CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING

Non-Final OA §112§DP
Filed
Apr 29, 2025
Examiner
OUSPENSKI, ILIA I
Art Unit
1644
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Bristol-Myers Squibb Company
OA Round
2 (Non-Final)
78%
Grant Probability
Favorable
2-3
OA Rounds
2y 7m
To Grant
98%
With Interview

Examiner Intelligence

Grants 78% — above average
78%
Career Allow Rate
850 granted / 1097 resolved
+17.5% vs TC avg
Strong +20% interview lift
Without
With
+20.5%
Interview Lift
resolved cases with interview
Typical timeline
2y 7m
Avg Prosecution
42 currently pending
Career history
1139
Total Applications
across all art units

Statute-Specific Performance

§101
1.7%
-38.3% vs TC avg
§103
10.6%
-29.4% vs TC avg
§102
19.0%
-21.0% vs TC avg
§112
17.3%
-22.7% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1097 resolved cases

Office Action

§112 §DP
DETAILED ACTION 1. The present application is being examined under the pre-AIA first to invent provisions. 2. A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after allowance or after an Office action under Ex Parte Quayle, 25 USPQ 74, 453 O.G. 213 (Comm'r Pat. 1935). Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, prosecution in this application has been reopened pursuant to 37 CFR 1.114. Applicant's submission filed on 01/05/2026 has been entered. 3. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. 4. Claims 32-37 are rejected under 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the applicant regards as the invention. Claim 32 is indefinite, because the first instance of recitation of “the nivolumab” lacks proper antecedent basis in the preceding part of the claim. Claims 33-37 are indefinite, because they encompass the indefinite limitations of the claim(s) on which they depend. In view of the above, a person of ordinary skill in the art cannot unequivocally interpret the metes and bounds of the claims so as to understand how to avoid infringement. Applicant is reminded that any amendment must point to a basis in the specification so as not to add New Matter. See MPEP 714.02 and 2163.06. 5. The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP §§ 706.02(l)(1) - 706.02(l)(3) for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/process/file/efs/guidance/eTD-info-I.jsp. 6. Claims 18-23, 26-27 and 29-31 are rejected on the ground of nonstatutory double patenting as being unpatentable over the claims of U.S. Patent No. 12479917. In the office action dated 06/16/2025 (section 10), the present claims were provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over the claims of copending application USSN 17/287838. In the Notice of Allowance dated 10/03/2025 (section 1), the provisional rejection was withdrawn to permit the present application to issue first. USSN 17/287838 issued as US ‘917 on 11/25/2025. Accordingly, the ground of provisional rejection over USSN 17/287838 are presently reinstated as non-provisional double patenting rejection over US ‘917. Although the claims at issue are not identical, they are not patentably distinct from each other because the instant claims are anticipated by the claims of US ‘917, which recite a method of treating metastatic NSCLC comprising administering to the subject nivolumab in combination with platinum doublet chemotherapy comprising carboplatin and paclitaxel, wherein the nivolumab is administered once every 3 weeks (claims 1-2 and 19-20), wherein at least 1% of tumor cells exhibit membrane PD-L1 expression (claim 4). A person of skill in the art would have been aware that the standard route of nivolumab administration is by intravenous infusion. Further, a person of skill in the art would have readily understood that if a tumor with at least 1% of tumor cells exhibiting membrane PD-L1 expression is treatable with nivolumab, a tumor with at least 10% of tumor cells exhibiting membrane PD-L1 expression would also be treatable with nivolumab, because it was known that patients with higher PD-L1 expression are more likely to benefit from anti-PD-1 treatment. The limitations of instant claims 20-23 and 26-27 are either routine in the art or inherent in US ‘917 claims. 7. Claims 18-27 and 29-36 are rejected on the ground of nonstatutory double patenting as being unpatentable over the claims of U.S. Patent No. 12528865. In the office action dated 06/16/2025 (section 10), the present claims were provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over the claims of copending application USSN 17/385636. In the Notice of Allowance dated 10/03/2025 (section 1), the provisional rejection was withdrawn to permit the present application to issue first. USSN 17/385636 issues as US ‘865 on 01/20/2026. Accordingly, the ground of provisional rejection over USSN 17/385636 are presently reinstated as non-provisional double patenting rejection over US ‘865. Although the claims at issue are not identical, they are not patentably distinct from each other because the instant claims are anticipated by the claims of US ‘865, which recite a method of treating advanced NSCLC comprising administering to the subject nivolumab once every 3 weeks, wherein at least 50% of tumor cells express PD-L1 (claims 1-3), further comprising administering platinum-based doublet chemotherapy comprising carboplatin and paclitaxel (claims 12-14), wherein the treatment is further combined with surgery (claim 11). 8. Claims 18-27 and 29-36 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over the claims of copending applications USSN 18/778430, published as US 20250011466 (of record), and 19/141978, published as US 20260000757. Although the claims at issue are not identical, they are not patentably distinct from each other because the instant claims are anticipated by or obvious over the claims of each of the copending applications, either alone or in view of Korman et al. (US 20090217401) and/or Brahmer et al. (2010; both of record). USSN ‘430 recites a method of treating NSCLC comprising administering nivolumab once every 3 weeks and platinum-based doublet chemotherapy comprising carboplatin and paclitaxel (claims 1-2, 8, 10 and 13-14). It would have been obvious to one of ordinary skill in the art at the time the invention was made to select patients whose tumor cells exhibited membrane PD- L1 expression, based on Brahmer's teachings that only such patients experienced tumor regressions in response to anti-PD-1 treatment (see p. 3170). USSN ‘978 recites a method of treating metastatic NSCLC comprising administering nivolumab (claims 185, 188, 191) and platinum doublet chemotherapy comprising carboplatin and paclitaxel (claims 192 and 196-197), wherein tumor cells express PD-L1 (claim 203). Although USSN ‘978 claims do not specifically exemplify administering nivolumab once every 3 weeks, it was within the skill in the art to adjust administration schedule according to the needs of the patient, in particular since such administration schedule was suggested by Korman (e.g. [0451]) for anti-PD-1 antibodies including antibody "5C4," now known as nivolumab. This is a provisional nonstatutory double patenting rejection because the patentably indistinct claims have not in fact been patented. 9. Claim 28 is objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all relevant limitations of the base claim and any intervening claims. 10. Any inquiry concerning this communication or earlier communications from the examiner should be directed to ILIA I OUSPENSKI whose telephone number is (571)272-2920. The examiner can normally be reached 8:30 AM – 5 PM. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Daniel Kolker can be reached at 571-272-3181. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /ILIA I OUSPENSKI/ Primary Examiner, Art Unit 1644
Read full office action

Prosecution Timeline

Apr 29, 2025
Application Filed
Jun 12, 2025
Non-Final Rejection — §112, §DP
Sep 16, 2025
Response Filed
Jan 05, 2026
Request for Continued Examination
Jan 07, 2026
Response after Non-Final Action
Jan 16, 2026
Non-Final Rejection — §112, §DP
Mar 18, 2026
Response Filed

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12600776
ANTI-L1CAM ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF AND CHIMERIC ANTIGEN RECEPTOR COMPRISING SAME
2y 5m to grant Granted Apr 14, 2026
Patent 12590153
TREATMENT OF PD-L1-NEGATIVE MELANOMA USING AN ANTI-PD-1 ANTIBODY AND AN ANTI-CTLA-4 ANTIBODY
2y 5m to grant Granted Mar 31, 2026
Patent 12590154
CANCER IMMUNOTHERAPY BY DISRUPTING PD-1/PD-L1 SIGNALING
2y 5m to grant Granted Mar 31, 2026
Patent 12583903
CONSTRUCTION OF CHIMERIC ANTIGEN RECEPTOR TARGETING CD20 ANTIGEN AND ACTIVITY IDENTIFICATION OF ENGINEERED T CELLS THEREOF
2y 5m to grant Granted Mar 24, 2026
Patent 12583934
ANTI-CD26 ANTIBODIES AND USES THEREOF
2y 5m to grant Granted Mar 24, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

2-3
Expected OA Rounds
78%
Grant Probability
98%
With Interview (+20.5%)
2y 7m
Median Time to Grant
Moderate
PTA Risk
Based on 1097 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in for Full Analysis

Enter your email to receive a magic link. No password needed.

Free tier: 3 strategy analyses per month